Oral Answers to Questions

Debate between Zubir Ahmed and Josh Newbury

Tuesday 21st October 2025 Commons Chamber

[Josh Newbury (Cannock Chase) (Lab)]

15. What steps he is taking to ensure that women have access to menopause treatments on the NHS.

[The Parliamentary Under-Secretary of State for Health and Social Care (Dr Zubir Ahmed)]

We have already made excellent progress, turning commitments in the women’s health strategy into tangible action. We are delivering 5.2 million extra appointments, which includes tackling gynaecology waiting lists. We know, though, that more needs to be done for women experiencing the menopause and on improving awareness and access to treatment. Menopause Mandate has long campaigned, alongside many Members in this House, for the menopause to be included in the NHS health check. I hope to be able to say more soon, but rest assured that we have heard those calls.

[Josh Newbury]

Earlier this year, a constituent came to speak to me about shortages of the one hormone replacement therapy drug that was working for her after years of misdiagnoses and ineffective treatment. She told me that GPs have very low awareness of menopause and often recommend alternatives that cause adverse reactions, leaving her and many other women paying for private advice and treatment and taking time off work. Will the Minister update the House on what the Department is doing to address HRT shortages and to improve training for GPs so that millions of women get the support that they need?

[Dr Ahmed]

I thank my hon. Friend for highlighting this crucial issue. The majority of the more than 70 HRT products are in good supply, but we are aware of shortages affecting certain estradiol patches, and we are engaging with suppliers to expedite deliveries wherever we can. We have issued guidance to healthcare professionals under the serious shortage protocols methodology to enable community pharmacists to supply alternatives where appropriate. Furthermore, we are committed to funding research into women’s health, and we have invested approximately £5 million through the National Institute for Health and Care Research scheme into menopause research, including studies for new treatments to improve outcomes for women experiencing the menopause.